Treating Chronic Pain in the Shadow of Addiction
Release Date: February 09, 2007
Expiration Date: February 09, 2010
Balancing the treatment of chronic pain and the risk of development or exacerbation of addictive disorder remains a medical challenge. Patients have a right to the most effective and rapid pain relief available. At times, this edict necessitates the treatment of a chronic pain patient who is at risk of addiction, or with active addictive disorder, with opioids. After conducting a comprehensive assessment of the patient and the reported pain, a strategic stepwise therapeutic approach is considered a rational method to improve care and contain risk.
The program will address these issues, as well assist clinicians in identifying aberrant behaviors suggestive of addictive disorder, and provide suggestions and recommendations for treating chronic pain patients who present with or develop addictive disorder.
This activity is designed for physicians, pharmacists, physician assistants, and nurses who have an interest in enhancing their knowledge and understanding of pain management.
Upon completion of this activity, participants should be able to:
- Differentiate the five steps of chronic pain management
- Describe three aberrant behaviors attributed to chronic pain patients with addictive disease
- Identify three benefits that are derived from using a strategic precautionary approach to patient assessment and management for the chronic pain patient
- Illustrate at least one activity related to deployment of an exit strategy
This activity is eligible for credit through February 9, 2010. After this date, this activity will expire and no further credit will be awarded.
There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. Certificates may be printed immediately after completing the online self-assessment and evaluation.
Dr. Penelope P. Ziegler, FASAM, is medical director emeritus of Williamsburg Place and the William J. Farley Center in Williamsburg, Virginia. Dr. Ziegler is a board certified addiction psychiatrist and certified fellow of the American Society of Addiction Medicine. She is also an associate clinical professor of psychiatry at Virginia Commonwealth University in Richmond, Virginia.
Dr. Ziegler has been working in the field of addiction medicine for more than 20 years. She currently serves on the Board of Directors for both the American Society of Addiction Medicine and American Academy of Addiction Psychiatry. Her special interests include addictive disease in health care professionals and women, the relationship of addiction in sexual trauma, and the challenging relationship of pain and addiction.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MediCom Worldwide, Inc. and Medical Learning Solutions. MediCom Worldwide, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour(s) of Continuing Education Credit. Universal Activity Number: 827-999-07-084-H01-P Knowledge-based CPE activity.
Accreditation Statement: This activity has been planned and implemented through the joint sponsorship of MediCom Worldwide, Inc. and Medical Learning Solutions. MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 07-184-179
It is the policy of MediCom Worldwide, Inc. to plan and implement educational activities in accordance with the ACCME, ACPE and California Board of Nursing. As a provider, it is the policy of MediCom Worldwide, Inc. to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities.
All program planners, faculty, and providers are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity.
Faculty Financial Disclosure
The presenting faculty reported the following: Dr. Penelope Ziegler has disclosed that she has no significant relationships with the grantor, Cephalon, Inc., or any other commercial company whose products and services may be related to her presentation.
Planner and Provider Financial Disclosure
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, executive director and Alan Vogenberg, RPh, FASCP, clinical advisor have nothing to disclose.
Jeffrey Gudin, MD was the clinical reviewer for this activity and has nothing to disclose. Ruth Widmer, medical writer of Corona Productions has nothing to disclose.
Conflict of Interest Resolution
To identify and resolve conflicts of interest the educational content was fully peer reviewed by a member of the MediCom Worldwide, Inc. Clinical Content Review Committee who has nothing to disclose. The resulting activity was found to provide educational content that is current, evidence based, and commercially balanced.
In accordance with MediCom Worldwide, Inc. policy, the audience is advised of the following disclosures regarding unlabeled or unapproved uses of drugs or devices: Dr. Ziegler indicated that her presentation would include the discussion of anticonvulsants and tricyclic antidepressants in the treatment of chronic pain. These drugs are not approved by the FDA for this use in the United States.
Dr. Ziegler indicated that her presentation would not include the discussion of products that have not been approved by the FDA for any use in the United States.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft®Silverlight™.
This activity is supported by an independent educational grant
from Cephalon, Inc.
©2007 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.